Aim: Schizophrenia (SZ) and bipolar disorder (BD) have been known to share genetic and environmental risk factors, and complex gene-environmental interactions may contribute to their pathophysiology. In contrast to high genetic overlap between SZ and BD, as revealed by genome-wide association studies, the extent of epigenetic overlap remains largely unknown. In the present study, we explored whether SZ and BD share epigenetic risk factors in the same manner as they share genetic components.
S CHIZOPHRENIA (SZ) AND BIPOLAR disorder (BD) are classified as major psychiatric disorders with overlapping psychotic symptoms. They have been known to share genetic and environmental risk factors, 1, 2 and complex gene-environmental interaction may contribute to the development of SZ and BD. 3, 4 Family, twin, and adoption studies suggest correlations in familial and genetic liabilities associated with SZ and BD, 5, 6 and both phenotypic and genetic overlaps have also been suggested with other psychiatric disorders. [7] [8] [9] [10] Among the varying degrees of overlaps in genetic factors in psychiatric disorders, previous studies using the data of genome-wide association studies (GWAS) have shown a high genetic correlation between SZ and BD, 11 and the highest significant overlap of polygenic risk between SZ and BD. 12 Epigenetic factors, including DNA methylation, have been considered to play an important role in gene-environment interactions because they are affected by environmental factors 3, 13 and contribute to long-lasting alteration of gene expression. 14 A number of epigenetic studies investigating SZ and BD have used post-mortem brains and peripheral tissues for research, and these have been reviewed elsewhere. [15] [16] [17] [18] We previously performed comprehensive DNA methylation analysis using promoter tiling arrays to explore epigenetic differences between a pair of monozygotic twins, one of whom had BD, and detected the hypermethylation of serotonin transporter gene (SLC6A4) in the bipolar twin. 19 In the study, the hypermethylation of SLC6A4 was also detected in post-mortem brains, suggesting that a part of alteration of DNA methylation is common in the brain and the peripheral tissue. The correlations of epigenetic changes between blood and the brain have also been demonstrated in healthy subjects 20 and in animal models of psychiatric disorders. 21 These results suggest the availability of peripheral blood in epigenetic studies of psychiatric disorders.
A recent, large-scale methylome-wide association study (MWAS) on approximately 1500 subjects revealed significant differential DNA methylation in more than 100 sites in blood cells of subjects with SZ. 22 The top findings were extensively validated by a pyrosequencing assay using independent sample sets, and included hypomethylation of CpG sites in family with sequence similarity 63, member B (FAM63B), Rho GTPase activating protein 26 (ARH-GAP26), CTAGE family member 11, pseudogene (CTAGE11P), TBC1 domain family member 22A (TBC1D22A), and intergenic region (IR) on chromosome 16. This study was the first MWAS of psychiatric disorders using an unbiased genome-wide approach. However, whether these epigenetic changes in SZ are shared with BD remains unknown, except for a recent replication study of FAM63 in BD. 23 Here, we performed focused bisulfite pyrosequencing analyses to investigate DNA methylation levels of CpG sites in the top five candidate regions detected in the SZ MWAS 22 using whole blood samples from patients with BD and control subjects (CT). The purpose of this study was to explore whether SZ and BD share epigenetic risk factors as well as genetic components, and to explore whether they have possible distinctive epigenetic signatures.
METHODS Samples
All DNA samples extracted from whole blood in BD patients (n = 450) and CT samples (n = 457) were provided by the Department of Psychiatry, Fujita Health University School of Medicine, and the Department of Neuropsychiatry, The University of Tokyo. BD was diagnosed according to the DSM-IV 24 by at least two experienced psychiatrists, based on unstructured interviews and a review of medical records. Controls were chosen based on short interviews (n = 67) and the Mini-International Neuropsychiatric Interview (n = 390) and satisfied the following conditions: (i) no current or past physical or psychiatric diagnoses; and (ii) no first-degree relatives with SZ or BD. All subjects were Japanese. Age was matched between groups (CT: 45.2 AE 10.7 years; BD: 46.2 AE 13.1 [mean AE SD]); however, the maleto-female ratio could not be matched (CT: 280:180; BD: 194:256). Written, informed consents were obtained from all participants, and our study was approved by the Human Genome Research Ethics Committee in collaborating research institutes.
DNA methylation analysis by pyrosequencing assays
CpG sites examined by pyrosequencing assays were essentially the same as those found in the previous report. 22 As for primers, we used the primer sets of FAM63B and ARHGAP26, similar to the method used in the previous study; 22 however, we redesigned new primer sets for CTAGE11P, TBC1D22A, and IR on chromosome 16, using MethPrimer. 25 This was done because we could not optimize the experimental conditions in our experimental settings. As a result, one additional CpG site at CTA-GE11P (chr13: 75795544, GRh37/hg19) was newly measured in this study. The information of each primer set is shown in Table S1 .
Genomic DNA was bisulfite-converted using Epitect 96 bisulfite kits (Qiagen, Hilden, MD, USA) in accordance with the manufacturer's protocol. The bisulfite-converted DNA was used as input material for polymerase chain reaction (PCR) in a total reaction volume of 50 μL, containing 5 μL of 10 × PCR Amplification Buffer (Invitrogen, Carlsbad, CA, USA), 10 μL of 5 M betaine (Sigma Aldrich, St. Louis, MO, USA), 3 μL of 50 mM MgCl 2 (Invitrogen), 1 μL of 10 mM dNTP (Promega, Madison, WI, USA), 2 μL each of 10 μM primers, 2 ng of Single-Stranded DNA Binding Protein (Promega), 5 U of Platinum Taq DNA Polymerase (Invitrogen), and 1 μL of bisulfite-modified genomic DNA. The thermocycling conditions were an initial incubation at 95 C for 3 min followed by 40 cycles each of 10 s at 98 C, 30 s at 55 C or 58 C (only for TBC1D22A), and 15 s at 72 C. Pyrosequencing assays were performed using the PCR product of bisulfite-converted DNA according to the manufacturer's protocol of PyroMark Q96 Vacuum Workstation (Qiagen). Briefly, the mixture of 1.5 μL of streptavidin-sepharose beads (Amersham Biosciences, Piscataway, NJ, USA), 40 μL of PyroMark Binding Buffer (Qiagen), and 37 μL of PCR product was shaken at 1400 r.p.m. for 10 min at room temperature. After preparing 40 μL annealing buffer mixed with 0.4 μM sequencing primer in the PSQ 96 Plate (Qiagen), the vacuum tool was lowered into the wells of the PCR plate to capture the beads with the PCR product. After flushing the tool with 70% ethanol, denaturation solution (0.2 N NaOH) and wash buffer, the tool was lowered into the wells to release the beads. The mixture of templatesequencing primer was transferred onto a PSQ 96 Plate for heating at 80 C for 2 min, and then cooled to room temperature. Sequencing reactions were performed using a PyroMark Gold Q96 Reagents Kit (Qiagen) according to the manufacturer's protocol. According to the allele quantification algorithm of the software provided by the manufacturer (PSQ96MA2.1.1 software, Qiagen), the percentages of methylation were calculated from the raw data.
For testing the accuracy of pyrosequencing methods in the common marmoset, samples containing various amounts of unmethylated and methylated marmoset genomic DNA were used. Unmethylated marmoset genomic DNA was prepared by whole genome amplification using a GenomiPhiv2 kit (GE Healthcare Life Science, Pittsburgh, PA, USA). Fully methylated DNA was prepared by treating unmethylated DNA with SssI (New England Biolabs, Ipswich, MA, USA).
Effects of antipsychotics on DNA methylation
To investigate the effects of antipsychotics, we measured the DNA methylation status using nonhuman primates administered with risperidone. Six adult male common marmosets (CLEA Japan, Inc., Tokyo, Japan) were divided into two groups. The medicated group (n = 3; mean age AE SD, 3.78 AE 0.47 years) was administered risperidone at 0.1 mg/kg (Wako Chemical, Tokyo, Japan), suspended in 2 mL/kg of 0.5% methylcellulose as vehicle (Wako Chemical), and the control group (n = 3; mean age AE SD, 3.38 AE 0.46 years) was given only vehicle. All of them were administered orally, once a day, for 28 days. After drug administration, peripheral blood cells were collected in EDTA-coated tubes and centrifuged for 10 min at 11 500 g. The centrifuged peripheral blood cells components were hemolyzed with 0.2% NaCl and stored at −80 C. Genomic DNA was purified using phenol/chloroform extraction. CpG sites of three of the five candidate regions (FAM63B, ARHGAP26, and IR on chromosome 16) have been evolutionarily conserved between humans and the common marmoset. We designed primers for the pyrosequencing assay for these CpG sites using MethPrimer. 25 The information of each primer set is shown in Table S2 . All animal experiments were approved by the Institutional Animal Care and Use Committee and conducted according to the guidelines of the Central Institute for Experimental Animals (Kanagawa, Japan), which comply with the Guidelines for Proper Conduct of Animal Experiments, published by the Science Council of Japan Animal Care.
Effects of cell composition on DNA methylation
To examine the effects of blood cell composition on DNA methylation, we examined the DNA methylation patterns of the five candidate regions in different cell types from human whole blood, using the iMethyl Database of the Iwate Tohoku Medical Megabank Organization (http://imethyl.iwate-megabank. org/index.html). 26 We retrieved average and SD of CpG methylation levels in monocytes, CD4+ T cells, and neutrophils from over 100 control subjects.
Statistical analysis
For primary analysis, we examined the association between the DNA methylation level of each CpG site and diagnosis by a multiple regression analysis considering DNA methylation level of each CpG site as a dependent variable, and diagnosis, age, and sex as independent variables using IBM SPSS 22 (IBM, Chicago, IL, USA). In case the effect of diagnosis was significant, we subsequently compared the DNA methylation level between diagnoses by the Student's t-test. A P-value of <0.05 was defined as statistically significant.
RESULTS

DNA methylation analysis for SZ MWAS: Top five findings in BD
We tested DNA methylation levels at the 14 CpG sites in the top five genes, of which 13 CpG sites were reported in the SZ MWAS, 22 using the genomic DNA derived from whole blood of CT (n = 457) and BD (n = 450) samples. Samples were excluded from the statistical analysis when the quality of the pyrogram at any CpG site failed. We compared mean DNA methylation levels of the 13 CpG sites in CT samples, between the SZ MWAS 22 and our study. DNA methylation levels were significantly correlated between the two studies (Pearson's R = 0.788, Fig. 1 ). Except for the two CpG sites in CTAGE11P, a robust correlation was obtained (R = 0.963, Fig. 1 ). This remarkably high consistency at most of the examined sites highlighted the robustness of our replication study by pyrosequencing. To evaluate the relation between DNA methylation of each CpG site and the diagnosis, we first performed a multiple regression analysis with the DNA methylation level of each CpG site as a dependent variable, and diagnosis, age, and sex as independent variables. We then compared DNA methylation differences between the CT and subjects with BD by Student's t-test.
FAM63B
FAM63B was a top-hit in the SZ MWAS, and three CpG sites in its exon were reported to be hypomethylated in the samples from subjects with SZ. 22 In our sample set after quality control (QC; n = 902), DNA methylation levels of all three CpG sites in FAM63B were significantly affected only by diagnosis, and they were also significantly hypomethylated in the subjects with BD (Table 1 and Fig. 2a ).
ARHGAP26 and CTAGE11P
ARHGAP26 was the second top hit in the SZ MWAS, and pyrosequencing validation detected hypomethylation of three CpG sites in its promoter region in the samples from subjects with SZ. 22 CTAGE11P was the third top hit, and two CpG sites in the downstream region of this gene also showed significant hypomethylation in subjects with SZ. 22 In our analysis, DNA methylation levels of these five CpG sites in the two genes and an additional CpG site in CTAG11P were not affected by diagnosis (Table 1) .
TBC1D22A
The fourth top-ranked finding in the SZ MWAS was TBC1D22A, and three CpG sites in its intron showed hypomethylation in the samples from subjects with SZ. 22 In our sample set after QC (N = 873), DNA methylation levels of all three CpG sites in TBC1D22A were significantly affected only by diagnosis. In contrast to the finding for SZ, these CpG sites were significantly hypermethylated in the subjects with BD (Table 1 and Fig. 2b ). 
IR on chromosome 16
The fifth top finding in the SZ MWAS was IR on chromosome 16. Pyrosequencing detected hypomethylation at two CpG sites located at chr16: 54209779-54209801 in subjects with SZ. 22 In our sample set after QC (n = 879), DNA methylation levels of these two CpG sites were significantly affected by diagnosis, and that of one of the CpG sites (position 2) was also significantly affected by age (P = 0.046). We detected significant hypomethylation of two CpG sites in the samples from subjects with BD, by the Student's t-test (Table 1 and Fig. 2c) .
Estimation of the effects of antipsychotics using the common marmoset
We attempted to assess the effect of antipsychotics using the blood samples from the common marmoset treated with risperidone. Several CpG sites among the three candidate regions have been evolutionarily conserved between humans and the common marmoset (Fig. 3a) , and thus, we measured DNA methylation levels in this study. To confirm the quantitative capability of each primer set, we prepared each standard curve using unmethylated and methylated DNA. Except for one of the CpG sites of IR on chromosome 16 (position 1), positive correlations between the measured and the expected DNA methylation level were observed (R = 0.985-0.998, Fig. S1 ), demonstrating the applicability of the assay to find subtle changes in DNA methylation. We excluded one CpG site of IR on chromosome 16 (position 1) from analysis. Consequently, we observed that none of these sites showed significant differences in the DNA methylation level between the risperidone-treated and control groups (Fig. 3b) .
Consideration of cellular heterogeneity
Differences in blood cell composition may affect DNA methylation pattern.
23,27-29 We investigated the DNA methylation level of 13 CpG sites in T cells, monocytes, and neutrophils using the iMethyl Database. 26 DNA methylation of all the 13 CpG sites in T cells was higher than that in neutrophils. DNA methylation levels in T cells with CpG sites in all candidate regions, except TBC1D22A, were almost 100%; on the other hand, those in neutrophils with CpG sites in FAM63B, ARHGAP26, and TBC1D22A were almost 0%. DNA methylation patterns of monocytes were different between candidate regions (Fig. S2) . 
DISCUSSION
In the present study, we conducted a replication study of a previous Swedish SZ MWAS, using a relatively large number of Japanese BD and CT samples. By focusing on the top-ranked findings related to SZ, we have highlighted the common and unique epigenetic changes associated with SZ and BD. Efforts have been made to rule out the effect of inter-researcher variations by measuring identical CpG sites with as identical methods as possible. This has led to a quite high consistency assay of DNA methylation levels at all candidate regions, except CTAGE11P (Fig. 1) . CTAGE11P is a pseudogene and its function is unknown. Ethnic differences of DNA methylation in some genes have been reported, [30] [31] [32] and DNA methylation of the Table 1 ). CT, control. and intergenic region (IR) on chromosome 16. Two of the three CpG sites in FAM63B, one of the three CpG sites in ARHGAP26, and both the CpG sites in IR on chromosome 16 in humans were conserved in marmosets. CpG in humans and marmosets is denoted as hPos and mPos, respectively. The following versions of genomes were used for alignments: hg19/GRCh37 (human), CSAC 2.1.4/panTro4 (chimpanzee), WUGSC 2.0.2/ponAbe2 (orangutan), BGI CR_1.0/rheMac3 (rhesus), Macaca_fascicu-laris_5.0/macFas5 (crab-eating monkey), MUGSC3.2/calJac3 (marmoset), GRCm38/mm10 (mouse), and RGSC 6.0/rn6 (rat). Pos; position. (b) Results of the pyrosequencing assay of whole blood samples from marmosets treated with risperidone. The medicated group (n = 3) was administered risperidone, and the control group (n = 3) was given only vehicle for 28 days. Note that differences were not significant (FAM63B mPos1: P = 0.117; mPos2: P = 0.220; mPos3: P = 0.131; ARHGAP26 mPos1: P = 0.538; mPos2: P = 0.465; mPos3: P = 0.578; IR in Chr16 mPos2: P = 0. two CpG sites in CTAGE11P might be affected in a similar manner.
We detected hypomethylation in the CpG sites of FAM63B and IR on chromosome 16 in the samples from subjects with BD. The methylation changes were robust after Bonferroni correction, suggesting that DNA methylation at these CpG sites could be common epigenetic changes for SZ and BD. A recent study using MassARRAY assays targeting the two CpG sites, which correspond to FAM63B_position 1 and 3, with blood samples from BD patients and CT showed that both sites are significantly hypomethylated in patients with BD. 23 The present study also replicated that FAM63B is a common epigenetic risk gene for SZ and BD. The role of FAM63B in the pathophysiology of SZ and BD remains unclear. Previous studies have reported that FAM63B is a part of the networks regulated by micro-RNA that can be related to neuronal differentiation and dopaminergic gene expression, [33] [34] [35] and that its gene expression is high in the pineal body, which takes a role as the formulation of the circadian clock. 36 Alteration of DNA methylation in FAM63B may cause disruptions of these functions and invite the onset of psychiatric disorders.
On the other hand, although the CpG sites in TBC1D22A were found to be significantly hypomethylated in the SZ MWAS, we detected hypermethylation in the same CpG sites in the subjects with BD, suggesting that DNA methylation at the CpG sites in TBC1D22A could be a distinctive epigenetic change for SZ and BD. The methylation change in only one of three CpG sites was significant after Bonferroni correction; however, these findings need to be validated in other populations.
Although methylation changes are replicable and robust, each absolute difference between BD and CT at the CpG sites in FAM63B, TBC1D22A, and IR on chromosome 16 was small (0.8-2.3%). This may be attributable to the heterogeneity of disease state, aging, sex difference, and other unknown factors, though we have matched the confounding factor as much as we could. Another explanation would be the heterogeneity of blood cells. Because the examined CpG sites showed blood-cell-type-dependent methylation status (Fig. S2) , cell-specific analyses will be needed to understand the functional role of these epigenetic changes.
Previous studies have reported that antipsychotics and mood stabilizers have some effects on the epigenetic status of brain cells and peripheral blood. [37] [38] [39] [40] [41] [42] Because of the absence of drug information in our sample set, we investigated the effects of antipsychotics on DNA methylation in the candidate regions using a nonhuman primate, the common marmoset, administered with risperidone. Although we examined the evolutionarily conserved CpG sites in three candidate regions (FAM63B, ARHGAP26, and IR on chromosome 16), we did not observe any possible effects of risperidone on DNA methylation. Although the effects of antipsychotics on DNA methylation in the other two candidate regions remain unclear, these findings suggest that some of the MWAS findings were not interpreted by the effects of antipsychotics.
Blood consists of various cell types with different DNA methylation profiles, and cell composition may consequentially be a confounding factor. [27] [28] [29] The previous study utilizing the array-based methylation database found the difference of DNA methylation between cell types at the nearest probe for FAM63B_ position 3. 23 Through the analysis of the data from the whole-genome bisulfite sequencing-based methylation database, we observed cell-type dependent DNA methylation profiles at all 13 CpG sites (Fig. S2 ). This suggests that DNA methylation changes in patients may partially be attributable to changes in cell composition. However, considering that changes in BD involve both hypo-and hypermethylations at CpG, which have similar cell-type-dependent DNA methylation profiles, changes in cell composition cannot fully explain methylation differences.
There are some limitations of this study. First, we could not obtain important clinical information of the patients, which would be confounding factors, such as severity of symptoms, physical examinations, and medication status. Second, in the marmoset experiments, although we investigated the effect of risperidone on DNA methylation, there was no data for mood stabilizers or other antipsychotics. In addition, the number of marmoset samples was too small, and the results of the effects of risperidone on DNA methylation might be false negatives.
In addition to genetic components, epigenetic factors could also be shared in the etiology of SZ and BD. More comprehensive epigenetic studies on BD, such as MWAS, will uncover the extent of the similarities and differences among epigenetic factors.
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